
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Recipient : Famar
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Under this agreement, Medicom has acquired the ownership of the BIMATOPROST 0.3 mg/mL, 3ml dossier which is already registered in the UK and 5 EU countries with plans to commercialise the asset globally.
Product Name : Zimed
Product Type : HPAPI
Upfront Cash : Undisclosed
February 10, 2021
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Recipient : Famar
Deal Size : Undisclosed
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Famar
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Under the agreement, Medicom has acquired the ownership of the pharmaceutical dossier of Zimed (bimatoprost), a preservative free eye drop solution, which is already registered in the UK and 5 EU countries with plans to commercialise the asset globally.
Product Name : Zimed
Product Type : HPAPI
Upfront Cash : Undisclosed
February 09, 2021
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Famar
Deal Size : Undisclosed
Deal Type : Acquisition
